drugset / Trial / NCT03815448

Summary

This multicentre randomized placebo-controlled clinical trial aims to evaluate whether methotrexate (MTX) has effects of relieving symptoms and reducing inflammation on advanced knee osteoarthritis (OA) with inflammatory phenotype. Participants will be randomly allocated to either MTX group or placebo group receiving MTX or placebo once a week. The primary outcomes are effusion-synovitis volume measured by magnetic resonance imaging (MRI) and knee pain assessed by visual analogue scale (VAS).

Timeline

Start
2019-07-18
Primary completion
2023-11-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 15 mg Oral